Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Common Equity: 2019-2024

Historic Common Equity for Keros Therapeutics (KROS) over the last 6 years, with Dec 2024 value amounting to $571.6 million.

  • Keros Therapeutics' Common Equity rose 32.04% to $703.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $703.6 million, marking a year-over-year increase of 32.04%. This contributed to the annual value of $571.6 million for FY2024, which is 72.04% up from last year.
  • Per Keros Therapeutics' latest filing, its Common Equity stood at $571.6 million for FY2024, which was up 72.04% from $332.2 million recorded in FY2023.
  • Over the past 5 years, Keros Therapeutics' Common Equity peaked at $571.6 million during FY2024, and registered a low of $243.2 million during FY2021.
  • For the 3-year period, Keros Therapeutics' Common Equity averaged around $393.7 million, with its median value being $332.2 million (2023).
  • In the last 5 years, Keros Therapeutics' Common Equity skyrocketed by 1,445.89% in 2020 and then decreased by 7.09% in 2021.
  • Yearly analysis of 5 years shows Keros Therapeutics' Common Equity stood at $261.7 million in 2020, then dropped by 7.09% to $243.2 million in 2021, then grew by 14.08% to $277.4 million in 2022, then grew by 19.75% to $332.2 million in 2023, then spiked by 72.04% to $571.6 million in 2024.